These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 26279065)
1. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065 [TBL] [Abstract][Full Text] [Related]
2. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018 [TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol. Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974 [TBL] [Abstract][Full Text] [Related]
4. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114 [TBL] [Abstract][Full Text] [Related]
5. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. Hartmann JA; McGorry PD; Schmidt SJ; Amminger GP; Yuen HP; Markulev C; Berger GE; Chen EYH; de Haan L; Hickie IB; Lavoie S; McHugh MJ; Mossaheb N; Nieman DH; Nordentoft M; Riecher-Rössler A; Schäfer MR; Schlögelhofer M; Smesny S; Thompson A; Verma SK; Yung AR; Nelson B Psychother Psychosom; 2017; 86(5):292-299. PubMed ID: 28903120 [TBL] [Abstract][Full Text] [Related]
6. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial. Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540 [TBL] [Abstract][Full Text] [Related]
7. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032 [TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748 [TBL] [Abstract][Full Text] [Related]
9. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis. Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856 [TBL] [Abstract][Full Text] [Related]
10. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167 [TBL] [Abstract][Full Text] [Related]
11. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study. Smesny S; Milleit B; Schaefer MR; Hesse J; Schlögelhofer M; Langbein K; Hipler UC; Berger M; Cotter DR; Sauer H; McGorry PD; Amminger GP Schizophr Res; 2017 Oct; 188():110-117. PubMed ID: 28126360 [TBL] [Abstract][Full Text] [Related]
12. Youth depression alleviation: the Fish Oil Youth Depression Study (YoDA-F): A randomized, double-blind, placebo-controlled treatment trial. Rice SM; Hickie IB; Yung AR; Mackinnon A; Berk M; Davey C; Hermens DF; Hetrick SE; Parker AG; Schäfer MR; McGorry PD; Amminger GP Early Interv Psychiatry; 2016 Aug; 10(4):290-9. PubMed ID: 25130262 [TBL] [Abstract][Full Text] [Related]
13. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Amminger GP; Schäfer MR; Schlögelhofer M; Klier CM; McGorry PD Nat Commun; 2015 Aug; 6():7934. PubMed ID: 26263244 [TBL] [Abstract][Full Text] [Related]
14. NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course. Nelson B; Amminger GP; Yuen HP; Markulev C; Lavoie S; Schäfer MR; Hartmann JA; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger G; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; McGorry PD NPJ Schizophr; 2018 Jun; 4(1):11. PubMed ID: 29941938 [TBL] [Abstract][Full Text] [Related]
15. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids. Mossaheb N; Papageorgiou K; Schäfer MR; Becker J; Schloegelhofer M; Amminger GP Early Interv Psychiatry; 2018 Feb; 12(1):30-36. PubMed ID: 26362578 [TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Amminger GP; Chanen AM; Ohmann S; Klier CM; Mossaheb N; Bechdolf A; Nelson B; Thompson A; McGorry PD; Yung AR; Schäfer MR Can J Psychiatry; 2013 Jul; 58(7):402-8. PubMed ID: 23870722 [TBL] [Abstract][Full Text] [Related]
17. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978 [TBL] [Abstract][Full Text] [Related]
18. Polyunsaturated fatty acids in emerging psychosis: a safer alternative? Schlögelhofer M; Amminger GP; Schaefer MR; Fusar-Poli P; Smesny S; McGorry P; Berger G; Mossaheb N Early Interv Psychiatry; 2014 Aug; 8(3):199-208. PubMed ID: 24861004 [TBL] [Abstract][Full Text] [Related]
19. Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls. Pawełczyk T; Trafalska E; Pawełczyk A; Kotlicka-Antczak M Early Interv Psychiatry; 2017 Dec; 11(6):498-508. PubMed ID: 26279283 [TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. McGorry PD; Nelson B; Phillips LJ; Yuen HP; Francey SM; Thampi A; Berger GE; Amminger GP; Simmons MB; Kelly D; Dip G; Thompson AD; Yung AR J Clin Psychiatry; 2013 Apr; 74(4):349-56. PubMed ID: 23218022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]